Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.55 |
| ▸ | ADRB3 | P13945 | 6/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.53 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.53 |
| ▸ | HTR1A | P08908 | 2/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.53 |
| ▸ | DRD1 | P21728 | 2/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.53 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.53 |
| ▸ | DRD3 | P35462 | 2/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4048311 | 1.00 | SLC6A3 (0.55) | SLC6A3CYP3A4CYP2D6SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL14126604 | 0.98 | HIF1A (0.54) | SLC6A3CYP3A4CYP2D6SLC6A2SLC6A4 | |
| Bromide SCHEMBL6286509 | 0.98 | SLC6A3 (0.53) | SLC6A3CYP3A4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL23367359 | 0.84 | SMN1; SMN2 (0.52) | SLC6A3SLC6A2SLC6A4ADRB3ADRB1 | |
| SCHEMBL10886485 | 0.83 | ADRB1 (0.56) | CYP3A4CYP2D6ADRB3ADRB1HIF1A | |
| SCHEMBL30488152 | 0.83 | ADRB1 (0.56) | CYP3A4CYP2D6ADRB3ADRB1HIF1A | |
| SCHEMBL25272115 | 0.83 | ADRB1 (0.56) | CYP3A4CYP2D6ADRB3ADRB1HIF1A | |
| SCHEMBL23384857 | 0.81 | ADRB3 (0.46) | SLC6A3CYP3A4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL16198513 | 0.81 | HTR2A (0.50) | SLC6A3CYP3A4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL16198555 | 0.81 | HTR2A (0.50) | SLC6A3CYP3A4CYP2D6SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6861438-B2 | Antiviral agents | PFIZER (US) | 2005-03-01 | — | — | US | claimed |
| EP-1458719-A1 | PYRIDOQUINOXALINE ANTIVIRALS | PHARMACIA & UPJOHN COMPANY (US) | 2004-09-22 | — | — | EP | claimed |
| US-20040138449-A1 | Antiviral agents | PHARMACIA & UPJOHN COMPANY | 2004-07-15 | — | — | US | claimed |
| US-20030207877-A1 | Pyridoquinoxaline antivirals | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | claimed |
| WO-2003053971-A1 | PYRIDOQUINOXALINE ANTIVIRALS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-03 | — | — | WO | claimed |
| US-6861438-B2 | Antiviral agents | PFIZER (US) | 2005-03-01 | — | — | US | disclosed |
| US-6852731-B2 | Antiviral compounds | PFIZER (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY | 2004-12-02 | — | — | US | disclosed |
| EP-1458719-A1 | PYRIDOQUINOXALINE ANTIVIRALS | PHARMACIA & UPJOHN COMPANY (US) | 2004-09-22 | — | — | EP | disclosed |
| US-20040138449-A1 | Antiviral agents | PHARMACIA & UPJOHN COMPANY | 2004-07-15 | — | — | US | disclosed |
| US-20030207877-A1 | Pyridoquinoxaline antivirals | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | disclosed |
| WO-2003053971-A1 | PYRIDOQUINOXALINE ANTIVIRALS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207877-A1 | Pyridoquinoxaline antivirals | IFNAR1, SARS1, ZC3HAV1 | SLC6A3 464/4885CYP3A4 601/4885CYP2D6 194/4885 |
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | ZC3HAV1, IRF3, IFNAR1 | SLC6A3 742/4885CYP3A4 703/4885CYP2D6 1361/4885 |
| US-20040138449-A1 | Antiviral agents | IRF3, IFNAR1, EIF2AK2 | SLC6A3 1295/4885CYP3A4 1526/4885CYP2D6 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.